Evidence from identical twin studies, familial aggregation, and consistently greater risk in Ashkenazim has shown that the greatest risk for developing Crohn's disease (CD) is genetic. A CD locus on chromosome 16, IBD1, was identified in 1996. IBD1 is the most consistently demonstrated inflammatory bowel disease (IBD) genetic locus, replicated in five out of seven studies. As part of an International IBD Genetics Consortium, we have recently provided definitive evidence for the IBD1 locus. Genotyping of 372 fully informative CD pedigrees randomly selected from 12 international IBD collaborators provided highly significant evidence for IBD1 (Lod 6.41). There was no evidence for IBD1 in 242 UC or mixed pedigrees. IBD1 appears to be particularly relevant in Asheknazim pedigrees. We recently found that stratifying pedigrees by early age at diagnosis and greater disease severity may greatly reduce linkage heterogeneity for IBD1. The overall goal of this application is to identify genetic mutations or polymorphisms responsible for IBD1. This goal will be achieved by the following specific aims: (1) we will identify linkage disequilibrium for IBD1 in Ashkenazim pedigrees. We will genotype markers spaced an average of 100 kb apart in 120 Ashkenazim trios with early-onset, severe CD. (2) For markers where there is evidence for linkage disequilibrium, we will extend evidence for the immediate region by genotyping adjacent markers, additional Ashkenazim CD pedigrees and non-Ashkenazim pedigrees ultimately identifying a minimal IBDI haplotype with maximal evidence of linkage disequilibrium. (3) We will perform mutation/polymorphism analysis on prioritized genes that map within this haplotype, and determine, using linkage disequilibrium analytic methods, which genetic variation is responsible for the genetic risk of Crohn's disease associated with the IBD1, chromosome 16 locus. Defining the IBD1 mutation for CD will be a major step in unraveling the etiology and pathophysiology of this enigmatic disease, improve genetic counseling and make possible novel preventative and therapeutic strategies.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK058189-02
Application #
6517804
Study Section
Epidemiology and Disease Control Subcommittee 2 (EDC)
Program Officer
Hamilton, Frank A
Project Start
2001-05-01
Project End
2006-04-30
Budget Start
2002-05-01
Budget End
2003-04-30
Support Year
2
Fiscal Year
2002
Total Cost
$387,106
Indirect Cost
Name
Johns Hopkins University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Okazaki, Toshihiko; Wang, Ming-Hsi; Rawsthorne, Patricia et al. (2008) Contributions of IBD5, IL23R, ATG16L1, and NOD2 to Crohn's disease risk in a population-based case-control study: evidence of gene-gene interactions. Inflamm Bowel Dis 14:1528-41
Brant, Steven R; Wang, Ming-Hsi; Rawsthorne, Patricia et al. (2007) A population-based case-control study of CARD15 and other risk factors in Crohn's disease and ulcerative colitis. Am J Gastroenterol 102:313-23
Bernstein, Charles N; Wang, Ming-Hsi; Sargent, Michael et al. (2007) Testing the interaction between NOD-2 status and serological response to Mycobacterium paratuberculosis in cases of inflammatory bowel disease. J Clin Microbiol 45:968-71
Park, Joon-Young; Farrance, Iain K G; Fenty, Nicola M et al. (2007) NFKB1 promoter variation implicates shear-induced NOS3 gene expression and endothelial function in prehypertensives and stage I hypertensives. Am J Physiol Heart Circ Physiol 293:H2320-7
Panhuysen, Carolien I; Karban, Amir; Knodle Manning, Alisa et al. (2006) Identification of genetic loci for basal cell nevus syndrome and inflammatory bowel disease in a single large pedigree. Hum Genet 120:31-41
Brant, Steven R; McGovern, Dermot P B (2005) NOD2, not yet: con. Inflamm Bowel Dis 11:507-9
Karban, Amir; Waterman, Matti; Panhuysen, Carolien I et al. (2004) NOD2/CARD15 genotype and phenotype differences between Ashkenazi and Sephardic Jews with Crohn's disease. Am J Gastroenterol 99:1134-40
Karban, Amir S; Okazaki, Toshihiko; Panhuysen, Carolien I M et al. (2004) Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis. Hum Mol Genet 13:35-45
Barmada, M Michael; Brant, Steven R; Nicolae, Dan L et al. (2004) A genome scan in 260 inflammatory bowel disease-affected relative pairs. Inflamm Bowel Dis 10:513-20
Barmada, M Michael; Brant, Steven R; Nicolae, Dan L et al. (2004) A genome scan in 260 inflammatory bowel disease-affected relative pairs. Inflamm Bowel Dis 10:15-22

Showing the most recent 10 out of 12 publications